✦ LIBER ✦

Cefepime pharmacodynamics in patients with extended spectrum β-lactamase (ESBL) and non-ESBL infections

✍ Scribed by Su Young Lee; Joseph L. Kuti; David P. Nicolau

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Strategies to overcome extended-spectrum

✍ David M. Livermore; Shazad Mushtaq; Tue Nguyen; Marina Warner 📂 Article 📅 2011 🏛 Elsevier Science 🌐 English ⚖ 131 KB

Clinical Implications, Risk Factors and

✍ Chia-Jung Hsieh; Yea-Huei Shen; Kao-Pin Hwang 📂 Article 📅 2010 🏛 Scientific Communications 🌐 English ⚖ 348 KB

Extended-spectrum β-lactamase (ESBL)-pro

✍ C.T. Moor; S.A. Roberts; G. Simmons; S. Briggs; A.J. Morris; J. Smith; H. Heffer 📂 Article 📅 2008 🏛 Elsevier Science 🌐 English ⚖ 394 KB

Clinical and Molecular Epidemiology of H

✍ Apisarnthanarak, Anucha; Kiratisin, Pattarachai; Mundy, Linda M. 📂 Article 📅 2008 🏛 University of Chicago Press 🌐 English ⚖ 395 KB

Prevalence of multidrug-resistant gram-n

✍ T.-Y. Men; J.-N. Wang; H. Li; Y. Gu; T.-H. Xing; Z.-H. Peng; L. Zhong 📂 Article 📅 2012 🏛 John Wiley and Sons 🌐 English ⚖ 104 KB

DP019 Validation of the new Etest ESBL s

📂 Article 📅 2003 🏛 Elsevier Science 🌐 English ⚖ 128 KB